

IFW

PTO/SB/21 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/749,714	
	Filing Date	December 31, 2003	
	First Named Inventor	Barbara CORDELL	
	Art Unit	1641	
	Examiner Name	Not Yet Assigned	
Total Number of Pages in This Submission	7	Attorney Docket Number	219002030710

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement, 3 pages <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Form 1449, 3 pages Return Postcard
<div>Remarks</div> <div>CUSTOMER NO. 25225</div>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	MORRISON & FOERSTER LLP James J. Mullen, III - 44,957
Signature	
Date	May 18, 2004


I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.	
Dated: May 18, 2004	Signature: (Rhea Amid)



PATENT
Docket No. 219002030710

CERTIFICATE OF MAILING BY "FIRST CLASS"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on May 18, 2004.


Rhea Amid

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Barbara CORDELL et al.

Serial No.: 10/749,714

Filing Date: December 31, 2003

For: MODULATION OF A β LEVELS BY β -
SECRETASE BACE2

Examiner: Not Yet Assigned

Group Art Unit: 1641

**INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents were previously submitted in an Information Disclosure Statement and/or Office Action directed to the related application Serial No. 09/886,143 filed 20 June 2001 and issued 30 March 2004 as U.S. Patent 6,713,276; accordingly, copies are not included herewith. This protocol conforms with 37 C.F.R. §1.98(d) and M.P.E.P. 609(A)(2). The Examiner is requested to make these documents of record in the application.

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of __ is enclosed.
 - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly, no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the amount of __ is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 219002030710. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: May 18, 2004

Respectfully submitted,

By: 

James J. Mullen, III, Ph.D.

Reg. No. 44,957


Morrison & Foerster LLP

3811 Valley Centre Drive, Suite 500

San Diego, California 92130-2332

Telephone: (858) 720-7940

Facsimile: (858) 720-5125

Form PTO-1449  (Use several sheets if necessary)	Docket Number 219002030710	Application Number 10/749,714
	Applicant Barbara CORDELL et al.	
	Filing Date December 31, 2003	Group Art Unit 1641
	Mailing Date May <u>18</u> , 2004	

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.		2002/0157122	Wong et al.	800	12	10/2002
	2.	08/1997	5,656,477	Vitek et al.	435	325	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
	3.	06/1998	EP 0 848 062	Europe			
	4.	08/1999	WO 99/34004	PCT			
	5.	04/2001	WO 01/23533	PCT			

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	6.	Acquati et al. <i>FEBS Letters</i> 468(1):59-64 (2000).
	7.	Bennett et al., <i>J Biol Chem</i> 275(27):20647-20651 (2000).
	8.	Bennett et al., <i>J Biol Chem</i> 275(48):37712-37717 (2000).
	9.	Cai et al., <i>Science</i> 259:514-516 (1993).
	10.	Checler, <i>J Neurochem</i> 65(4):1431-1444 (1995).
	11.	Citron et al., <i>Nature</i> 360:672-674 (1992).
	12.	Citron et al., <i>Neuron</i> 14:661-671 (1995).
	13.	Citron et al., <i>Neuron</i> 17:171-179 (1996).
	14.	Clark et al., <i>Arch Neurol</i> 50:1164-1172 (1993).
	15.	Farzan, <i>PNAS</i> 97(17):9712-9717 (2000).
	16.	Gen Bank accession no. AF050171 Homo Sapiens Aspartly Protease mRNA Complete CDs.
	17.	Glenner et al., <i>J Neurol Sci</i> 94:1-28 (1989).

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 219002030710	Application Number 10/749,714
	Applicant Barbara CORDELL et al.	
	Filing Date December 31, 2003	Group Art Unit 1641
	Mailing Date May <u>18</u> , 2004	

18.	Goodison et al., <i>J Neuropath and Exper Neurol</i> 52(3):192-198 (1993).
19.	Gouras et al., <i>PNAS</i> 97(3):1202-1205 (2000).
20.	Greenberg et al., <i>Neurology</i> 43:2073-2079 (1993).
21.	Haan et al., <i>Clin Neurol Neurosurg</i> 92(4):305-310 (1990).
22.	Haass et al., <i>Science</i> 286:916-919 (1999).
23.	Hardy, <i>Alzheimer's Disease Update</i> 10(2):239-247 (1994).
24.	Hardy, <i>Nat Gen</i> 1:233-234 (1992).
25.	Hardy, <i>TINS</i> 20(4):154-159 (1997).
26.	Hattori et al., <i>Nature</i> 405:311-319 (2000).
27.	Higaki et al., <i>J Biol Chem</i> 271(50):31885-31893 (1996).
28.	Higaki et al., <i>J Med Chem</i> 42:3889-3898 (1999).
29.	Higaki et al., <i>Neuron</i> 14:651-659 (1995).
30.	Hussein et al., <i>Mole and Cell Neurosci</i> 14:419-427 (1999).
31.	Ida et al., <i>J Biol Chem</i> 271(37):22908-22914 (1996).
32.	Itch et al., <i>J Neurol Sci</i> 116:135-141 (1993).
33.	Johnson-Wood et al., <i>PNAS USA</i> 94:1550-1555 (1997).
34.	Kalaria et al., <i>NeuroReport</i> 6(3):477-480 (1995).
35.	Kang et al., <i>Nature</i> 325:733-736 (1987).
36.	Kawai et al., <i>Brain Research</i> 623:142-146 (1993).
37.	Kitaguchi et al., <i>Nature</i> 331:530-532 (1988).
38.	Lannfelt et al., <i>Biochem Soc Trans</i> 22:176-179 (1993).
39.	Levy et al., <i>Science</i> 24:1124-1126 (1990).
40.	Li et al., <i>PNAS</i> 97(11):6138-6143 (2000).
41.	Lin et al., <i>PNAS</i> 97(4):1456-1460 (2000).
42.	Maat-Schieman et al., <i>Acta Neuropath</i> 88:371-378 (1994).
43.	Mandybur, <i>Acta Neuropath</i> 78:329-331 (1989).
44.	Mann et al., <i>Neurodegen</i> 1:201-215 (1992).
45.	Martin et al., <i>Am J Path</i> 145(6):1358-1381 (1994).
46.	Masliah et al., <i>J Neurosci</i> 16(18):5795-5811 (1996).
47.	Mullan et al., <i>Nat Gen</i> 1:345-347 (1992).
48.	Oyama et al., <i>J Neurochem</i> 62(3):1062-1066 (1994).

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 219002030710	Application Number 10/749,714
	Applicant Barbara CORDELL et al.	
	Filing Date December 31, 2003	Group Art Unit 1641
	Mailing Date May <u>18</u> , 2004	

49.	Pike et al., <i>J Neurochem</i> 64(1):253-265 (1995).
50.	Ponte et al., <i>Nature</i> 331:525-527 (1988).
51.	Roach, <i>Soc for Neurosci</i> [Abstract 180.21] 26:1-2 (2000).
52.	Saunders et al., <i>Science</i> 286:1255a (1999).
53.	Selkoe et al., <i>PNAS USA</i> 85:73441-7345 (1988).
54.	Selkoe et al., <i>PNAS USA</i> 97(11):5690-5692 (2000).
55.	Selkoe, <i>J Biol Chem</i> 271(31):18295-18298 (1996).
56.	Selkoe, <i>Nature</i> 399:A23-A31(1999).
57.	Selkoe, <i>PNAS</i> 97(11):5690-5692 (2000).
58.	Selkoe, <i>TINS</i> 16(10):403-409 (1993).
59.	Seubert et al., <i>Letts to Nature</i> 361:260-262 (1993).
60.	Shoji et al., <i>Science</i> 258:126-129 (1992).
61.	Sinha et al., <i>Letts to Nature</i> 402:537-540 (1999).
62.	Sinha et al., <i>PNAS USA</i> 96:11049-11053 (1999).
63.	Skovronsky et al., <i>J Biol Chem</i> 275(4):2568-2575 (2000).
64.	Solana, <i>Cytogen and Cell Gen</i> 89(3-4):177-184 (2000).
65.	Tanzi et al., <i>Nature</i> 331:528-530 (1988).
66.	Terry et al., ed., <i>Alzheimer Disease</i> , Raven Press Ltd., NY (1994) pp. 179-196
67.	Vassar et al., <i>Science</i> 286:735-7441 (1999).
68.	Vassar, <i>Science</i> 286(5440):735-741 (1999).
69.	Vinters, <i>Stroke</i> 18(2):311-324 (1987).
70.	Wattendorf et al., <i>J Neurol, Neurosurg, Psych</i> 58:699-705 (1995).
71.	Wisniewski et al., <i>Anns Neurol</i> 17(3):278-282 (1985).
72.	Wolfe et al., <i>J Med Chem</i> 41:6-9 (1998).
73.	Wolfe et al., <i>Nature</i> 398:513-517 (1999).
74.	Yamada et al., <i>J Neurol, Neurosurg, Psych</i> 56:543-547 (1993).
75.	Yan et al., <i>Letts Nature</i> 402:533-537 (1999).

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.